- Poster presentation
- Open Access
Unprecedented nosocoimal spread os vancomycin-resistant Enterococcus faecium in a tertiary-care hospital in Switzerland
© Senn et al; licensee BioMed Central Ltd. 2011
- Published: 29 June 2011
- Regional Hospital
- Enterococcus Faecium
- Rectal Swab
- Infection Control Measure
- Secondary Case
The incidence of vancomycin-resistant enterococci (VRE) remains sporadic in Switzerland. We report an unprecedented VRE (E.faecium van B) outbreak in a 900-bed tertiary care hospital and describe its molecular epidemiology.
VRE was detected in clinical specimens by standard procedures. Carriage screening was performed by rectal swab. Swabs were inoculated into an enrichment broth and grown on chromogenic VRE agar. Isolates were typed by PFGE.
In November 2010, a first case of VRE was detected in a urine culture. The investigation identified 3 secondary cases in roommates (asymptomatic carriage). A second clinical case was detected in January 2011. Four secondary cases were identified. Both index cases were previously hospitalized in the same regional hospital. All patients transferred from the regional hospital were screened for VRE. In addition, weekly screening was initiated in patients hospitalized in the epidemic ward.
In total, from November 2010 to March 2011, 31 VRE cases were identified: 4 in clinical specimens (urine 2, wound 2) and 27 in screening swabs. One patient presented a VRE bacteremia. Molecular analysis showed that all isolates except 2 had the same PFGE pattern. The 2 different strains had only a variation of 1 to 2 bands and were probably related to the outbreak. Infection control measures (contact isolation of carriers and roommates, quarantine of the epdiemic ward and reinforcement of environment disinfection) were implemented.
This the first report of a large VRE outbreak in Switzerland. Molecular typing confirmed the occurrence of an outbreak and showed that no sporadic case occurred during this period. The outbreak was controlled by implementation of strict infection control measures.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.